An Intragastric Gavage Technique for Controlled Helicobacter Infection in Mice

Executive Industry Relevance

Controlled intragastric gavage for Helicobacter infection in mice enables precise modeling of host-pathogen interactions, supporting early-stage target validation and mechanistic de-risking in gastrointestinal disease research. This approach provides reproducible infection parameters, facilitating predictive confidence in preclinical studies and informing portfolio decisions for anti-infective and immunomodulatory programs.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of host-pathogen mechanisms relevant to gastric disease.
• Supports functional validation of bacterial virulence factors and host response pathways.
• Facilitates biological de-risking by providing a controlled infection model.
• Improves predictive confidence for downstream therapeutic hypothesis testing.

Screening & Assay Development

• Establishes standardized infection conditions for reproducible compound screening.
• Allows quantitative assessment of bacterial colonization and host tissue response.
• Supports assay development for evaluating anti-Helicobacter agents or immunomodulators.
• Enables platform reuse for comparative studies across bacterial strains or interventions.

Translational & Preclinical Research

• Provides a disease-relevant system for modeling gastric pathologies linked to Helicobacter infection.
• Aligns preclinical findings with translational biomarker development for gastric disease.
• Supports risk-adjusted advancement of candidates targeting infection or inflammation pathways.
• Facilitates continuity from mechanistic discovery to preclinical validation.

Pipeline & Workflow Integration

This intragastric infection model bridges early discovery and preclinical research, enabling hypothesis-driven studies and quantitative readouts for lead identification and validation.

• Discovery Biology: Supports hypothesis testing on bacterial colonization, host response, and virulence factor function.
• Screening: Provides reproducible infection parameters for evaluating candidate efficacy.
• Analytics: Enables quantitative measurement of bacterial load and tissue pathology for comparative analysis.
• Translational Research: Connects mechanistic findings to disease-relevant biomarkers and preclinical endpoints.
• Enterprise Reuse: Offers a standardized, scalable model adaptable to various Helicobacter strains and intervention strategies.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in infection biology.
• Operational Value: Delivers standardized, reproducible, and scalable infection protocols.
• Strategic Value: Informs go/no-go decisions and enhances capital efficiency by reducing late-stage biological risk.
• Portfolio Impact: Enables risk-adjusted prioritization and advancement of anti-infective and immunomodulatory assets.

Implementation Considerations

• Requires expertise in animal handling and infection modeling.
• Needs access to phase contrast microscopy for bacterial viability assessment.
• Demands cross-team standardization of inoculum preparation and dosing.
• Adaptable to different Helicobacter species and mouse strains as supported by the protocol.
• Dependent on maintaining pathogen-free animal colonies and validated bacterial cultures.

Biopharma FAQs